CTLA4 and neoplasm: For example, RORC agonists combined with the checkpoint inhibitor anti-CTLA-4 could enhance Th17 cell differentiation, migration, and infiltration, inhibit Treg cell production, increase the function of anti-tumor effector T cells, and inhibit the growth of MC38 COAD cells.